Here's what will trigger the next fight over payments compliance

Processors and lenders are becoming increasingly wary of the rapid rise in peptide treatments like GLP-1s. If your practice offers these services or uses financing to sell them, you may face sudden disruptions in payment processing or higher scrutiny on loan applications. Banks view this sector as high-risk due to shifting FDA regulations and a surge in 'gray market' compounding pharmacies. Even if your business is fully compliant, you are likely to be grouped into a high-risk compliance bucket by auditors. For retailers and medical spa operators, this means the 'wellness' boom is a double-edged sword. While patient demand is high, the financial infrastructure supporting these transactions is under pressure. You should prepare for potential 'de-risking' where banks suddenly freeze accounts or stop supporting certain medical financing programs for injectable treatments. Keeping meticulous records of your sourcing and ensuring all prescription protocols are followed will be vital for maintaining your ability to offer monthly payment plans to patients.

Source: American Banker — Top News

← Return to the library· Submit a correction